Ignite Creation Date:
2025-12-25 @ 2:05 AM
Ignite Modification Date:
2026-03-11 @ 9:03 PM
Study NCT ID:
NCT01287260
Status:
COMPLETED
Last Update Posted:
2014-01-29
First Post:
2011-01-30
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
High Dose BAYA1040_Nifedipine: a Dose-comparative Study
Sponsor:
Bayer
Organization:
Study Overview
Official Title:
A Multicenter, Double-blind, Parallel-group Comparative Study Between Oral BAYA1040_CR 80 mg and 40 mg for 8 Weeks in Patients With Essential Hypertension for Whom Oral BAYA1040_CR 40 mg is Insufficient
Status:
COMPLETED
Status Verified Date:
2014-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a clinical study evaluating the superiority in efficacy and assess safety and tolerability of BAYA1040\_Nifedipine 80 mg/day (40 mg twice daily) compared with BAYA1040\_Nifedipine 40 mg/day (40 mg once daily) in patients with essential hypertension who are not at target blood pressure by BAYA1040\_Nifedipine 40 mg once daily treatment.
Detailed Description:
None
Study Oversight
Has Oversight DMC:
False
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?: